"Immunization, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
| Descriptor ID |
D007117
|
| MeSH Number(s) |
E02.095.465.425.400.485 E05.478.550.550
|
| Concept/Terms |
Immunization, Secondary- Immunization, Secondary
- Immunizations, Secondary
- Secondary Immunizations
- Immunization, Booster
- Booster Immunization
- Booster Immunizations
- Immunizations, Booster
- Secondary Immunization
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Secondary".
This graph shows the total number of publications written about "Immunization, Secondary" by people in this website by year, and whether "Immunization, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 3 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 2 | 3 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunization, Secondary" by people in Profiles.
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
-
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025 Dec; 21(1):2450120.
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
-
Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
-
Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones. Vaccine. 2024 May 22; 42(14):3337-3345.
-
Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV. AIDS. 2023 12 01; 37(15):2305-2310.
-
Safety of COVID-19 booster dose: is the juice worth the squeeze? Lancet Infect Dis. 2023 10; 23(10):1097-1099.
-
ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children. Vaccine. 2023 06 01; 41(24):3617-3626.
-
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022 03 05; 399(10328):924-944.
-
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.